Αρχική World News Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in Patients...

Promising Results Observed with Front-line Sintilimab Plus a Bevacizumab Biosimilar in Patients with Advanced HCC

Sintilimab, which has been approved in China for the treatment of Hodgkin’s disease, in combination with a bevacizumab biosimilar as first-line treatment of patients with advanced hepatocellular carcinoma (HCC) significantly improved survival compared to sorafenib, according to findings presented at the ESMO Asia Virtual Congress 2020, held 20 to 22 November 2020.

Zhenggang Ren of the Department of Hepatic Oncology, Zhongshan Hospital of Fudan University in Shanghai, China, presented data from the phase III efficacy part of the randomised, open-label, multicentre phase II/III ORIENT-32 (NCT03794440) study evaluating sintilimab plus a bevacizumab biosimilar versus sorafenib as first-line treatment for advanced HCC. The phase II part of the study demonstrated acceptable safety with the combination.

ORIENT-32 enrolled patients with unresectable or metastatic HCC who were naive for systemic HCC treatment. In phase III part, following 2:1 randomisation, 380 patients were treated with sintilimab at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks and 191 patients were treated with oral sorafenib at 400 mg twice daily. Stratification factors included macrovascular invasion and/or extrahepatic metastasis (presence versus absence), baseline alpha fetoprotein level (< 400 versus ≥400 ng/mL) and ECOG performance status (0 versus 1).

The primary endpoints were overall survival (OS) and progression-free survival (PFS) by independent radiographic review committee (IRRC) per RECIST v1.1.

Combination of sintilimab plus bevacizumab biosimilar showed significantly improved survival, thus meeting the study primary endpoints

Among the patients enrolled by data cut-off on 15 August 2020, the baseline characteristics were well balanced; the majority (94.2%) of patients had hepatitis B infection and 4.2% of patients had Child-Pugh B status of chronic liver disease.

With median follow-up of 10.0 months, median OS was significantly longer with the sintilimab plus bevacizumab biosimilar combination than with sorafenib, and the combination setting demonstrated a 43.1% decreased risk of all-cause death; median OS was not estimable (NE) compared to 10.4 months, respectively (hazard ratio [HR] 0.569; 95% confidence interval [CI] 0.431-0.751; p < 0.0001).

Similarly, improved PFS was also demonstrated, with a 43.5% decreased risk of progression assessed by IRRC per RECIST v1.1; median PFS with the combination was 4.6 months compared to 2.8 months with sorafenib (HR 0.565; 95% CI 0.455-0.701, p < 0.0001).

Promising-Results-Observed-with-Front-line-Sintilimab-Plus-a-Bevacizumab-Biosimilar-in-Patients-with-Advanced-HCC

Overall survival and progression-free survival, the primary endpoints in the ORIENT-32 study.

© Zhenggang Ren.

Overall benefit favoured the combination over sorafenib consistently across all the subgroups evaluated.

Efficacy-evaluable patients demonstrated a confirmed objective response rate (ORR; by IRRC per RECIST v1.1) of 20.5% (95% CI 16.5-25.1) with the combination versus 4.1% (95% CI 1.7-8.2) with sorafenib.

Among patients receiving at least one drug dose, any grade treatment related adverse events (TRAEs) occurred in 88.7% of patients receiving the combination versus 93.5% of sorafenib-treated patients. Grade 3/4 TRAEs were reported in 33.7% and 35.7% of patients, respectively.

Conclusions

According to the authors, sintilimab plus a bevacizumab biosimilar showed significant improvements in clinical benefits compared to sorafenib, as first-line treatment of patients with advanced hepatocellular carcinoma.

Funding for this study was reported from Innovent Biologics, Inc.

Reference             

LBA2 – Ren Z, Fan J, Xu J, et al. Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32). ESMO Asia Virtual Congress 2020 (20-22 November).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2021 ASCO Annual Meeting Research Round Up: Advances in Treating Lung Cancer, Breast Cancer, and Sarcoma

In the annual Research Round Up series, Cancer.Net Associate Editors answer the question, “What was the most exciting or practice-changing research in your field...

Avapritinib Not Superior to Regorafenib in Terms of Median PFS in Third-Line or Later Treatment of Patients with Unresectable or Metastatic GIST

Findings from an open-label, randomised, multicentre phase III VOYAGER study indicate that avapritinib is not superior to regorafenib in terms of median progression-free survival...

Patients less likely to rate cancer care as ‘very good’ during pandemic

Almost a third of cancer patients have reported receiving worse care since COVID-19 began, according to a new survey commissioned by Cancer Research UK. Whilst...

How to Avoid Spreading Harmful Chemo Chemicals to Members of Your Household

Cancer is not contagious, and neither is chemotherapy. However, harmful chemotherapy drugs can sometimes still be present in the bodily fluids of a person...

The right combination for early detection

The upcoming Early Detection of Cancer Conference brings together experts from multiple disciplines to share ground breaking research and progress in the field. Here...

Can’t Sleep? Tips for Coping with Insomnia

Insomnia* is common for cancer patients**, as well as for the general population. We frequently hear from our patients and their caregivers that sleeping through the night...